関連ニュース

Sanofi NASDAQ: SNY is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the compa

Q2 strengthened earnings visibility, with higher guidance and continued Dupixent momentum supporting the 2026 outlook. Newer launches are scaling faster, giving Sanofi a clearer path toward a more div

On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Trump's Gold Standard Childhood Vaccine Recommendations will be temporary. Sanofi is trading at a sign

Sanofi is rated a Buy, with 33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios. Dupixent remains Sanofi's key growth driver, with a

Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has a

Sanofi today announced discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis.

Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector